Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1

Clinical Cancer Research

Volumn 23, Issue 8, 2017, Pages 1920-1928

  Champiat, Stéphane ^a,b   Dercle, Laurent ^a   Ammari, Samy ^a   Massard, Christophe ^a   Hollebecque, Antoine ^a   Postel Vinay, Sophie ^a,b   Chaput, Nathalie ^a,b,c   Eggermont, Alexander ^a   Marabelle, Aurélien ^a,b   Soria, Jean Charles ^a,b   Ferté, Charles ^a,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c CNRS   (France)

^d Institut Gustave Roussy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI PD 1; ANTI PD L1; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERPROGRESSIVE DISEASE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 85018847861     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1741     Document Type: Article

References (35)

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
2. Robert C, Schachter J, Long GV, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus ipilimumab in advancedmelanoma. N Engl J Med 2015;372:2521-32.
3. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-smallcell lung cancer. N Engl J Med 2015;373:123-35.
4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
5. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
6. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20.
7. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
8. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
9. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016;34: 1510-7.
10. Lahmar J, Facchinetti F, Koscielny S, Ferte C, Mezquita L, Bluthgen MV, et al. Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC). J Clin Oncol 34, 2016 (suppl; abstr 9034).
11. Saada-Bouzid E, Defaucheux C, Karabajakian A, Palomar Coloma V, Servois V, Paoletti X, et al. Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD-1/PD-L1 inhibitors. J Clin Oncol 34, 2016(suppl; abstr 6072).
12. Ferte C, FernandezM, Hollebecque A, Koscielny S, Levy A,Massard C, et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res 2014;20:246-52.
13. Ferté C, Koscielny S, Albiges L, Rocher L, Soria J-C, Iacovelli R, et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment inmetastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. Eur Urol 2014; 65:713-20.
14. Nishino M, Dahlberg SE, Fulton LE, Digumarthy SR, Hatabu H, Johnson BE, et al. Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib. Acad Radiol 2016;23: 329-36.
15. Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 2011;47:2512-6.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, SargentD, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
18. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
19. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692-6.
20. Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013;14:428-36.
21. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 2012;24:331-41.
22. Landre T, Taleb C, Nicolas P, Des Guetz G. Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour? J Clin Oncol 34, 2016(suppl; abstr 3070).
23. Strannegård Ö, Thorén FB. Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha-can tumor immune escape after immunotherapy accelerate disease progression? Oncoimmunology 2016;5:e1091147.
24. Mellema WW, Burgers SA, Smit EF. Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: A case report. Lung Cancer 2015;87:201-3.
25. Kuriyama Y, Kim YH, Nagai H, Ozasa H, Sakamori Y,Mishima M. Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinasepositive lung cancer. Case Rep Oncol 2013;6:430-3.
26. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFRmutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298-303.
27. Iacovelli R, Massari F,Albiges L, Loriot Y, Massard C, Fizazi K, et al. Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment ofmetastatic renal cell carcinoma. Eur Urol 2015;68:154-60.
28. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-5.
29. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 2015;162:1242-56.
30. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
31. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternativeimmune checkpoints. NatCommun 2016;7:1-9.
32. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073-81.
33. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
34. Hölzel M, Tüting T. Inflammation-induced plasticity inmelanoma therapy and metastasis. Trends Immunol 2016;37:364-74.
35. Hölzel M, Bovier A, Tüting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013;13:365-76.